Saratov JOURNAL of Medical and Scientific Research

The value of tumor markers in prognos-ing the outcomes of treatment of patients with bladder cancer

Year: 2018, volume 14 Issue: №4 Pages: 661-666
Heading: Urology Article type: Review
Authors: Ponukalin A.N., Zakharova N.B., Skriptsova S.A., Fomkin R.N., Chekhonatskaya M.L.
Organization: Saratov State Medical University n.a. V I. Razumovsky, Scientific Research Institute of Fundamental and Clinical Uronephrology, Saratov State Medical University

The review analyzes the recent publications of the results of the use of molecular genetic markers of bladder cancer (RMP) in clinical practice. The prospects of application of a series of molecules determined in tumor tissue, serum, urine in the diagnosis of RMP are presented. One ofthe most promising areas of finding a marker forthe diagnosis and control of treatment of RMP in recent years are the study ofthe proteomic composition of urine.

1 Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for global burden of disease study. JAMA Oncol 2017; 3: 524-48
2 Kaprin AD, Starinskiy VV, Petrova GV. The state of cancer care in Russia in 2015 Moscow, 2016; 236 p.
3 Kaprin AD, Starinskiy VV, Petrova GV. Malignant neoplasm in Russia in 2014 (morbidity and mortality). Moscow, 2016 250 p.
4 Nosov DA, Bolotina LV, Vorobyov NA, et al. Practical recommendations for drug treatment of bladder cancer. Malignant tumor 2016; (4): 338-42
5 Sylvester RJ, Meijden АР, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Та T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49 (3): 466-77. DOI: 10.1016/j.eururo.2005.12.031. PMID: 16442208 URL: https://www.ncbi.nlm.nih.gOv/pubmed/1 6442208
6 Caprin AD. Modern concepts of bladder cancer treatment. Modern Oncology 2004; 4: 34-18
7 Kaprin AD, Apolikhin Ol, Alekseev BYa, et al. Comparison of the EORTC and CUETO prognostic models in non- muscle-invasive bladder cancer. Cancer Urology 2018; 14 (2): 162-70. URL: https://doi.Org/1 0.17650/1726-9776- 2018-14-2-162-170
8 Mikich DH. Organ-preserving treatment for invasive bladder cancer. Oncourology 2005; (2): 27-32
9 Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. Actas Urol Esp 2010; 34(1): 51-62
10 Liedberg F, Mansson W. Lymph node metastasis in bladder cancer. Eur Urol 2006; 49: 13-21
11 Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 2013; 64 (4): 639-53. URL: https://
12 Glaser AP, Fantini D, Shilatifard A, et al. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol 2017; 14 (4): 215-29. URL:
13 Kirkali Z, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66 (6A): 4-34
14 Al-Shukri SA, Tkachuk VN, Volkov NM, Dubina MV Prognostic molecular genetic markers of bladder cancer (literature review). Oncology 2009; (2): 78-84
15 Volpe A, et al. Bladder tumor markers: a review of the literature. The International Journal of Biological Markers 2008; 23 (4): 249-61
16 Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions on the urothelium. Urol Oncol 2010; 28 (4): 409-28
17 Polishchuk LA, Telegeeva PG, Stakhovsky AE, et al. New specific molecular diagnostic markers in urologic diseases. Laboratory diagnostics 2010; 4 (54): 46-51
18 Pu XY. et al. The value of combined use of surviving, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 2008; 134(6): 659-665
19 Ponukalin AN, Popkov VM, Zakharova NB, Mikhailov VYu. Tumor markers in the diagnosis stage of invasiveness of bladder cancer. Medical Journal of Bashkortostan 2013; 8 (2): 213-17
20 Konety BR, Lotan Y, Konety BR. Urothelial bladder cancer: biomarkers for detection and screening. BJU International 2008; 102(9): 1234-41
21 Castro J, et al. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and CYFRA 21-1. Cancer Invest 2008; 26 (4): 407-18
22 Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. J. Urology 2008; 72: 869-72
23 ShirodkarSP, Lokeshwar VB. Bladder tumor markers: from hematuria to molecular diagnostics where do we stand? Expert review ofAnticancer Therapy 2008; 8 (7): 1111-23
24 Jacobs LB, LeeTC, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244-72
25 Fergelot P, Rioux-Leclercq N, Patard JJ. Molecular Pathways of tumor angiogenesis and new targeted therapeutical approches in renal cancer. Prog Urol 2005; 15 (6): 1021-9
26 GarcHa-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identies association between VEGF polymorphism and bladder cancer risk. PLoS Genet 2007 Feb 23; 3 (2): e29. DOI: 10.1371/journal.pgen.0030029
7 Goddard JC, Sutton CD, Furness PN, et al. Microvessel density at presentation predicts subsequent muscle invasion in supercial bladder cancer. Clin Cancer Res 2003 Jul; 9 (7): 2583-6
28 Stenzl A, Cowan NC, De Santis M, et al. Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. Actas Urol Esp 2010; 34(1): 51-62
29 Glybochko PV, Ponukalin AN, Zakharova NB, Shahapasyan NK. The value of markers of tumor growth and angiogenesis in the diagnosis of bladder cancer. Oncourology 2009; (2): 56-60
30 Al-Shukri SKh, Korneev IA, Yagmurov OD, et al. The role of tumor angiogenesis in the course of transitional Сell carcinoma of the bladder. Topical issues of pathological anatomy 2010; (2): 37-8
31 Popkov VM, Ponukalin NB, Zakharova NB. Vascular endothelial growth factor in the diagnosis of metastases of muscle-invasive bladder cancer. Oncourology 2016; 12 (2): 53-7
32 Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanism and therapeutic implication. EXS 2006; 96: 223-68
33 Rey del J, Prat E, Ponsa I, et al. Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors. ВМС Cancer 2010; 10:280-91
34 Bollman D, Bollman M, Bankfalvi A, et al. Quantitative molecular grading of bladder tumours: A tool for objective assessment of the biological potential of urothelial neoplasias. Oncol Rep 2009; 21: 39-47
35 Lindgren D, Frikvesi A, Guidionsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010; 70 (9): 3463-72
36 Tritschler ML, Sommer J. Straub, et al. Urinary cytology in Era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urology 2010; 76(3): 677-80
37 He H, Han C, Hao L, Zang G. Immunocyt test compared to cytology in the diagnosis of bladder cancer: a meta- analysis. Oncol Lett 2016; 12: 83-8. DOI: 10.3892/ol.2016.4556
38 TodenhoferT, Hennenlotter J, EsserM, etal. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013; 121: 252-60. DOI: 10.1002/cncy.21247

2018_4_661-666.pdf286.7 KB

No votes yet